← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Peptide Logic, Llc
San Diego, CA
$9,238,021
Total funding
10
Grants
Funding over time
peak $3.4M · FY2016–22$5M$3.8M$2.5M$1.3M$0
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$9,238,021 · 10
By mechanism
R44$5,950,812 · 3
R43$3,287,209 · 7
Investigators at Peptide Logic, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Peripherally-Restricted Long-Acting Somatostatin Receptor 4 (LA-SSTR4) Agonists for Pain$1,585,395
R44 · FY2019 · DA
Peripherally-restricted and long-acting kappa-opioid receptor (LA-KOR) agonists for pain$1,524,027
R44 · FY2018 · DA
Peripherally-restricted and long-acting kappa-opioid receptor (LA-KOR) agonists for pain$1,431,363
R44 · FY2019 · DA
Peripherally-Restricted Long-Acting Somatostatin Receptor 4 (LA-SSTR4) Agonists for Pain$1,410,027
R44 · FY2020 · NS
Peptide-antibody conjugate kappa-opioid receptor (PAC-KOR) agonists for treatment of chronic itch$499,449
R43 · FY2022 · NS
Long acting and peripherally restricted kappa-opioid receptor agonists for acute migraine treatment$499,290
R43 · FY2021 · NS
Prolactin monoclonal antibodies (PRL-mAbs) for the treatment of female-predominant pain syndromes$496,611
R43 · FY2021 · NS
Peripherally-restricted and long-acting MAS1(LA-MAS1) agonists for pain$347,799
R43 · FY2019 · DA
Bi-Functional Peptides to Block Vasodilation and Vascular Leakage in Sepsis$298,121
R43 · FY2017 · GM
PERIPHERALLY-RESTRICTED LONG-ACTING SOMATOSTATIN RECEPTOR TYPE 4 (LA-SSTR4) AGONISTS FOR PAIN$279,411
R43 · FY2018 · DA
PERIPHERALLY-RESTRICTED LONG-ACTING SOMATOSTATIN RECEPTOR TYPE 4 (LA-SSTR4) AGONISTS FOR PAIN$260,861
R43 · FY2018 · DA
Long-Acting Peripherally-Restricted Peptidic Kappa Opioid Receptor Agonists for Pain$206,927
R43 · FY2016 · DA
Long acting and peripherally restricted kappa-opioid receptor agonists for acute migraine treatment$199,432
R43 · FY2022 · NS
Prolactin monoclonal antibodies (PRL-mAbs) for the treatment of female-predominant pain syndromes$199,308
R43 · FY2022 · NS